RxDoctor Payments Data

Michael Bavlsik, MD

Internal Medicine · Saint Louis, MONPI 1295752756

Payments from drug & device makers

$757in general payments, 2019–2025

Across 41 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$127
  • AbbVie$125
  • Pfizer$116
  • GSK$60
  • Novo Nordisk$51
  • Scilex Pharmaceuticals Inc.$46
  • plus $233 from 11 others

What the payments were for

  • Food & beverage$68290%
  • Education$7510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$757 in reported general payments places this provider in the 65th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$168,062
Medicare patients
393
Services billed
3,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban190$210,647
OzempicSemaglutide124$167,468
JardianceEmpagliflozin90$114,017
MounjaroTirzepatide78$105,873
MyrbetriqMirabegron100$85,854
TrulicityDulaglutide47$67,319
XareltoRivaroxaban29$42,225
BiktarvyBictegrav/Emtricit/Tenofov Ala11$41,166
FarxigaDapagliflozin Propanediol27$31,821
JanuviaSitagliptin Phosphate32$30,592
RybelsusSemaglutide18$26,218
Tresiba Flextouch U-200Insulin Degludec16$25,161
TivicayDolutegravir Sodium11$24,433
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog19$24,033
DescovyEmtricitabine/Tenofov Alafenam11$23,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$116$210,647190 claims
Novo NordiskOzempic, Rybelsus$51$193,686142 claims
Lilly USA, LLCMounjaro, Trulicity$41$173,192125 claims
Boehringer IngelheimJardiance, Spiriva Respimat$22$122,168105 claims
Astellas Pharma US IncMyrbetriq$127$85,854100 claims
GSKArexvy, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$60$62,338144 claims
Johnson & JohnsonXarelto, Invokana$15$50,89441 claims
NovartisEntresto$12$19,46415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →